Oncogenic activity of retinoic acid receptor γ Is exhibited through activation of the Akt/NF-κB and Wnt/β-catenin pathways in cholangiocarcinoma

Molecular and Cellular Biology

Volumn 33, Issue 17, 2013, Pages 3416-3425

  Huang, Gui Li ^a   Luo, Qi ^a   Rui, Gang ^a   Zhang, Wei ^a   Zhang, Qiu Yan ^b   Chen, Qing Xi ^b   Shen, Dong Yan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN E; CYCLINE; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; RETINOIC ACID RECEPTOR GAMMA; WNT PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL; CARCINOGENESIS; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUDE MOUSE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TUMOR XENOGRAFT;

ANIMALS; BETA CATENIN; BILE DUCT NEOPLASMS; BILE DUCTS; CELL CYCLE; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, RETINOIC ACID; UP-REGULATION; WNT SIGNALING PATHWAY;

EID: 84883527714     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00384-13     Document Type: Article

References (38)

1. Aljiffry M, Walsh MJ, Molinari M. 2009. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J. Gastroenterol. 15:4240-4262.
2. Khan SA, Toledano MB, Taylor-Robinson SD. 2008. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB 10:77-82.
3. Gronemeyer H, Gustafsson JA, Laudet V. 2004. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3:950- 964.
4. Marinelli A, Bossi D, Pelicci PG, Minucci S. 2007. A redundant oncogenic potential of the retinoic receptor (RAR) alpha, beta and gamma isoforms in acute promyelocytic leukemia. Leukemia 21:647-650.
5. Purton LE, Dworkin S, Olsen GH, Walkley CR, Fabb SA, Collins SJ, Chambon P. 2006. RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J. Exp. Med. 203:1283-1293.
6. Zhao X, Demary K, Wong L, Vaziri C, McKenzie AB, Eberlein TJ, Spanjaard RA. 2001. Retinoic acid receptor-independent mechanism of apoptosis of melanoma cells by the retinoid CD437 (AHPN). Cell Death Differ. 8:878-886.
7. Goranov BB, Campbell Hewson QD, Pearson AD, Redfern CP. 2006. Overexpression of RARgamma increases death of SH-SY5Y neuroblastoma cells in response to retinoic acid but not fenretinide. Cell Death Differ. 13:676-679.
8. Walkley CR, Olsen GH, Dworkin S, Fabb SA, Swann J, McArthur GA, Westmoreland SV, Chambon P, Scadden DT, Purton LE. 2007. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 129:1097-1110.
9. Zhao X, Graves C, Ames SJ, Fisher DE, Spanjaard RA. 2009. Mechanism of regulation and suppression of melanoma invasiveness by novel retinoic acid receptor-gamma target gene carbohydrate sulfotransferase 10. Cancer Res. 69:5218-5225.
10. Chen CF, Goyette P, Lohnes D. 2004. RARgamma acts as a tumor suppressor in mouse keratinocytes. Oncogene 23:5350-5359.
11. Aggarwal S, Kim SW, Cheon K, Tabassam FH, Yoon JH, Koo JS. 2006. Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells. Mol. Biol. Cell 17:566-575.
12. Hughes PJ, Zhao Y, Chandraratna RA, Brown G. 2006. Retinoidmediated stimulation of steroid sulfatase activity in myeloid leukemic celllines requires RARalpha and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways. J. Cell. Biochem. 97:327-350.
13. Masia S, Alvarez S, de Lera AR, Barettino D. 2007. Rapid, nongenomic actions of retinoic acid on phosphatidylinositol-3-kinase signaling pathway mediated by the retinoic acid receptor. Mol. Endocrinol. 21:2391- 2402.
14. Dey N, De PK, Wang M, Zhang H, Dobrota EA, Robertson KA, Durden DL. 2007. CSK controls retinoic acid receptor (RAR) signaling: a RAR-c- SRC signaling axis is required for neuritogenic differentiation. Mol. Cell. Biol. 27:4179-4197.
15. Yan TD, Wu H, Zhang HP, Lu N, Ye P, Yu FH, Zhou H, Li WG, Cao X, Lin YY, He JY, Gao WW, Zhao Y, Xie L, Chen JB, Zhang XK, Zeng JZ. 2010. Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma. Cancer Res. 70:2285-2295.
16. Shen DY, Zhan YH, Wang QM, Rui G, Zhang ZM. 2013. Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma. Liver Int. 33: 137-148.
17. Zhou X, Yang J, Wang Y, Li W, Li-Ling J, Deng Y, Zhang M. 2012. Cucurbitacin B inhibits 12-O-tetradecanoylphorbol 13-acetate-induced invasion and migration of human hepatoma cells through inactivating mitogen-activated protein kinase and PI3K/Akt signal transduction pathways. Hepatol. Res. 42:401-411.
18. Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H, Katano M. 2010. Inhibition of Wnt signaling pathway decreases chemotherapy- resistant side-population colon cancer cells. Anticancer Res. 30: 2041-2048.
19. Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D, Beckmann JS, Joseph JM, Muhlethaler-Mottet A, Gross N. 2009. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene 28:2245-2256.
20. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. 1999. The cyclin D1 gene is a target of the beta-catenin/ LEF-1 pathway. Proc. Natl. Acad. Sci. U. S. A. 96:5522-5527.
21. Zhang H, Zhang X, Wu X, Li W, Su P, Cheng H, Xiang L, Gao P, Zhou G. 2012. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/beta-catenin pathway. Cancer Lett. 323:106-113.
22. Fukunaka K, Saito T, Wataba K, Ashihara K, Ito E, Kudo R. 2001. Changes in expression and subcellular localization of nuclear retinoic acid receptors in human endometrial epithelium during the menstrual cycle. Mol. Hum. Reprod. 7:437-446.
23. Albrechtsson E, Ohlsson B, Axelson J. 2002. The expression of retinoic acid receptors and the effects in vitro by retinoids in human pancreatic cancer cell lines. Pancreas 25:49-56.
24. Chakravarti N, Lotan R, Diwan AH, Warneke CL, Johnson MM, Prieto VG. 2007. Decreased expression of retinoid receptors in melanoma: entailment in tumorigenesis and prognosis. Clin. Cancer Res. 13:4817-4824.
25. Kumar A, Kaur J, Chattopadhyay TK, Mathur M, Ralhan R. 2004. Differential expression of retinoic acid receptors in normal and malignant esophageal tissues. J. Exp. Ther. Oncol. 4:1-8.
26. Briggs CD, Neal CP, Mann CD, Steward WP, Manson MM, Berry DP. 2009. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur. J. Cancer 45:33-47.
27. Hahnvajanawong C, Ketnimit S, Pattanapanyasat K, Anantachoke N, Sripa B, Pinmai K, Seubwai W, Reutrakul V. 2012. Involvement of p53 and nuclear factor-kappaB signaling pathway for the induction of G1- phase cell cycle Arrest of cholangiocarcinoma cell lines by isomorellin. Biol. Pharm. Bull. 35:1914-1925.
28. Batheja N, Suriawinata A, Saxena R, Ionescu G, Schwartz M, Thung SN. 2000. Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis. Mod. Pathol. 13:1265-1268.
29. Itatsu K, Sasaki M, Yamaguchi J, Ohira S, Ishikawa A, Ikeda H, Sato Y, Harada K, Zen Y, Sato H, Ohta T, Nagino M, Nimura Y, Nakanuma Y. 2009. Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase- 9 in cholangiocarcinoma induced by tumor necrosis factoralpha. Am. J. Pathol. 174:829-841.
30. Sirica AE. 2005. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41:5-15.
31. Liu ZH, He YP, Zhou Y, Zhang P, Qin H. 2011. Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM. Mol. Biol. Rep. 38:3075-3082.
32. Sadana P. 2012. Noncanonical mechanisms to regulate nuclear receptor signaling. Future Med. Chem. 4:1307-1333.
33. Prakobwong S, Gupta SC, Kim JH, Sung B, Pinlaor P, Hiraku Y, Wongkham S, Sripa B, Pinlaor S, Aggarwal BB. 2011. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis 32:1372-1380.
34. Schmitz KJ, Lang H, Wohlschlaeger J, Sotiropoulos GC, Reis H, Schmid KW, Baba HA. 2007. AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. World J. Gastroenterol. 13:6470-6477.
35. Sugimachi K, Taguchi K, Aishima S, Tanaka S, Shimada M, Kajiyama K, Tsuneyoshi M. 2001. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod. Pathol. 14: 900-905.
36. Tokumoto N, Ikeda S, Ishizaki Y, Kurihara T, Ozaki S, Iseki M, Shimizu Y, Itamoto T, Arihiro K, Okajima M, Asahara T. 2005. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int. J. Oncol. 27: 973-980.
37. Clevers H, Nusse R. 2012. Wnt/beta-catenin signaling and disease. Cell 149:1192-1205.
38. Yasuhara R, Yuasa T, Williams JA, Byers SW, Shah S, Pacifici M, Iwamoto M, Enomoto-Iwamoto M. 2010. Wnt/beta-catenin and retinoic acid receptor signaling pathways interact to regulate chondrocyte function and matrix turnover. J. Biol. Chem. 285:317-327.